Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

603 Search results.

Screening - GSK Milveterol COPD 100527

- 6/18/17 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Exercise Tolerance NCT01418248

- 12/16/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01418248

Eligibility Exercise Induced Asthma NCT01070888

- 12/16/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01070888

Eligibility Eosinophilic Bronchitis NCT02002754

- 12/13/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02002754

Eligibility Eosinophilic Asthma NCT01290887

- 12/13/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01290887

Eligibility EGFR Positive Non-small Cell Lung Cancer NCT01774721

- 12/13/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.; ODM derived from: https://clinicaltrials.gov/show/NCT01774721

Eligibility Difficult Asthma NCT01862289

- 11/23/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prevalence of Hyperventilation Syndrome in Difficult Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01862289

clinic internal medicine B SHIP-3 operational data lung function

- 10/30/19 - 1 form, 1 itemgroup, 58 items, 2 languages
Itemgroup: operational data lung function
operational data lung function form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name SHIP.SHIP3.IMB.LUF.LUFOPD. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617 The English version of this form is under development.

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Non-Serious Adverse Event; Serious Adverse Events; Concomitant Medications

- 10/30/19 - 1 form, 15 itemgroups, 105 items, 1 language
Itemgroups: Non-Serious Adverse Event, Serious Adverse Event, SAE - Type of Report, SAE- Randomisation, SAE - Seriousness, SAE - Relevant Concomitant Medications, SAE - Relevant Medical Conditions/ Risk Factors, SAE - Relevant Diagnostic Results, SAE - Rechallenge, SAE - Investigational Product, SAE - Investigational Product, SAE - Investigational Product , SAE - General Narrative Comments, SAE - Non clinical, Concomitant Medications
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Concomitant Medications Form

- 10/30/19 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: Concomitant Medication Details
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

CRB-65-Index

- 10/28/19 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CRB-65-Index
The CRB-65-Score is a clinical score to estimate the severity of a community acquired pneumonia. An outpatient therapy is likely to occur in patients with low risk (CRP-65/CURB = 0 Points). Taking other risk factors into account, patients with a CRB-65/CURB score higher than 1 should be considered to get hospitalised Source: Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82. Der CRB-65-Score ist ein klinisches Instrument um die Schwere einer ambulant erworbenen Pneumonie einzuschätzen. Patienten mit niedrigem Risiko (CRB-65 / CURB = 0) können meistens ambulant behandelt werden. Ab CRB-65 / CURB = 1 sollte unter Einbeziehung anderer Risikofaktoren die stationäre Aufnahme erwogen werden.

CURB-Index

- 10/28/19 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CURB-Index
The CURB-Score is a clinical score to estimate the severity of a community acquired pneumonia. An outpatient therapy is likely to occur in patients with low risk (CRP-65/CURB = 0 Points). Taking other risk factors into account, patients with a CRB-65/CURB score higher than 1 should be considered to get hospitalised Source: Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82. Der CURB-Score ist ein klinisches Instrument um die Schwere einer ambulant erworbenen Pneumonien einzuschätzen. Patienten mit niedrigem Risiko (CRB-65 / CURB = 0) können meistens ambulant behandelt werden. Ab CRB-65 / CURB = 1 sollte unter Einbeziehung anderer Risikofaktoren die stationäre Aufnahme erwogen werden.